If the manufacturer can be trusted, the 2010 reformulation of the popular opioid OxyContin was a success. Purdue Pharma, the drug's maker, put out a study last week showing reduced abuse, addiction and overdose of the drug since the new version hit the shelves.
But not everyone is convinced. Workers' compensation experts have criticized the study as a distraction from the bigger picture and possibly biased.
Paul Coplan and Aditi Kadakia, two researchers for Purdue Pharma, presented the results of the study last week at the 31st Annual Meeting of the American Academy of Pain Medicine ...
Comments